Last reviewed · How we verify
AVX502
At a glance
| Generic name | AVX502 |
|---|---|
| Sponsor | AlphaVax, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza (PHASE1, PHASE2)
- A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |